BioVie (BIVI) Expected to Announce Quarterly Earnings on Tuesday

BioVie (NASDAQ:BIVI) is expected to post its Q2 2026 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, February 9, 2026 at 4:00 PM ET.

BioVie (NASDAQ:BIVI) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.19).

BioVie Stock Performance

NASDAQ:BIVI opened at $1.24 on Tuesday. The firm has a market capitalization of $9.35 million, a price-to-earnings ratio of -0.18 and a beta of 0.36. BioVie has a 52-week low of $1.10 and a 52-week high of $20.40. The stock has a fifty day moving average of $1.34 and a 200 day moving average of $2.10.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in BioVie during the second quarter worth about $40,000. NewEdge Advisors LLC raised its holdings in shares of BioVie by 283.7% during the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock valued at $53,000 after buying an additional 40,000 shares in the last quarter. Jane Street Group LLC bought a new stake in BioVie in the 2nd quarter worth approximately $57,000. Two Sigma Investments LP purchased a new stake in BioVie in the third quarter worth approximately $62,000. Finally, Squarepoint Ops LLC purchased a new stake in BioVie in the third quarter worth approximately $63,000. Institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.